144 related articles for article (PubMed ID: 28295184)
1. The six-minute walk test is a valuable measure of functional change following chemotherapy for AL (light-chain) cardiac amyloidosis.
Decker I; Goodman SA; Phillips SE; Lenihan DJ; Cornell RF
Br J Haematol; 2017 May; 177(3):481-483. PubMed ID: 28295184
[No Abstract] [Full Text] [Related]
2. Case Report: Treatment of light-chain amyloidosis with daratumumab monotherapy in two patients.
Gran C; Gahrton G; Alici E; Nahi H
Eur J Haematol; 2018 Apr; 100(4):386-388. PubMed ID: 29226427
[TBL] [Abstract][Full Text] [Related]
3. A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis.
Cibeira MT; Oriol A; Lahuerta JJ; Mateos MV; de la Rubia J; Hernández MT; Granell M; Fernández de Larrea C; San Miguel JF; Bladé J;
Br J Haematol; 2015 Sep; 170(6):804-13. PubMed ID: 25974382
[TBL] [Abstract][Full Text] [Related]
4. Functional Cardiac Recovery and Hematologic Response to Chemotherapy in Patients With Light-Chain Amyloidosis (from the Stanford University Amyloidosis Registry).
Tuzovic M; Kobayashi Y; Wheeler M; Barrett C; Liedtke M; Lafayette R; Schrier S; Haddad F; Witteles R
Am J Cardiol; 2017 Oct; 120(8):1381-1386. PubMed ID: 28844519
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib-Containing Regimens for the Treatment of Newly Diagnosed and Relapsed Amyloid Light Chain Amyloidosis: A Single-Center Experience.
Jimenez-Zepeda VH; Duggan P; Neri P; Bahlis NJ
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e79-84. PubMed ID: 27101985
[TBL] [Abstract][Full Text] [Related]
6. Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement.
Badar T; Cornelison AM; Shah ND; Bashir Q; Parmar S; Patel K; Hosing C; Popat U; Weber DM; Thomas SK; Shah JJ; Orlowski RZ; Champlin RE; Qazilbash MH
Eur J Haematol; 2016 Oct; 97(4):342-7. PubMed ID: 26773409
[TBL] [Abstract][Full Text] [Related]
7. Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response.
Grogan M; Dispenzieri A; Gertz MA
Heart; 2017 Jul; 103(14):1065-1072. PubMed ID: 28456755
[TBL] [Abstract][Full Text] [Related]
8. Regression of cardiac wall thickness following chemotherapy and stem cell transplantation for light chain (AL) amyloidosis.
Meier-Ewert HK; Sanchorawala V; Berk J; Finn KT; Skinner M; Seldin DC; Ruberg FL
Amyloid; 2011 Jun; 18 Suppl 1():130-1. PubMed ID: 21838460
[No Abstract] [Full Text] [Related]
9. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
[TBL] [Abstract][Full Text] [Related]
10. The six-minute walk test in patients with AL amyloidosis: a single centre case series.
Pulido V; Doros G; Berk JL; Sanchorawala V
Br J Haematol; 2017 May; 177(3):388-394. PubMed ID: 28340285
[TBL] [Abstract][Full Text] [Related]
11. Decrease of B-type natriuretic peptide to less than 200 pg/mL predicts longer survival in cardiac immunoglobulin light chain amyloidosis.
Ishiguro K; Hayashi T; Igarashi T; Maruyama Y; Ikeda H; Ishida T; Shinomura Y
Int J Hematol; 2015 Aug; 102(2):200-4. PubMed ID: 26016720
[TBL] [Abstract][Full Text] [Related]
12. Recognizing Pinch Purpura as the First Manifestation of Light-chain Amyloidosis.
Öztürk E; Akay MO; Ferhanoğlu B
Turk J Haematol; 2018 Aug; 35(3):208-209. PubMed ID: 29553461
[No Abstract] [Full Text] [Related]
13. Diagnosis and treatment of Al amyloidosis.
Seldin DC
Clin Adv Hematol Oncol; 2003 Mar; 1(3):154-5. PubMed ID: 16224395
[No Abstract] [Full Text] [Related]
14. Harnessing Cardiac Regeneration as a Potential Therapeutic Strategy for AL Cardiac Amyloidosis.
Joshi S; Evangelisti A; Liao R; Alexander KM
Curr Cardiol Rep; 2020 Jan; 22(1):1. PubMed ID: 31932992
[TBL] [Abstract][Full Text] [Related]
15. Six-minute walk test (6MWT) in AL amyloidosis - baseline and 12-month follow-up after chemotherapy.
Flatman K; Foard D; Pyart E; Hughes G; Gaudia R; Kearney C; Elmi I; Bangova A; Libo-On P; Caringal-Galima J; Rowles E; Guillotte C; Hawkins P; Gillmore J; Lane T
Amyloid; 2017 Mar; 24(sup1):62-63. PubMed ID: 28434348
[No Abstract] [Full Text] [Related]
16. Intensive therapy in AL amyloidosis and light-chain deposition disease.
Mariette X; Clauvel JP; Brouet JC
Ann Intern Med; 1995 Oct; 123(7):553. PubMed ID: 7661505
[No Abstract] [Full Text] [Related]
17. Severe heart failure from light chain cardiomyopathy (cardiac amyloidosis).
Hofer JF; Wimmer G
Z Kardiol; 2003 Jan; 92(1):90-5. PubMed ID: 12545307
[TBL] [Abstract][Full Text] [Related]
18. Cardiac Care of Patients with Cardiac Amyloidosis.
Itzhaki Ben Zadok O; Kornowski R
Acta Haematol; 2020; 143(4):343-351. PubMed ID: 32408301
[TBL] [Abstract][Full Text] [Related]
19. JCS 2020 Guideline on Diagnosis and Treatment of Cardiac Amyloidosis.
Kitaoka H; Izumi C; Izumiya Y; Inomata T; Ueda M; Kubo T; Koyama J; Sano M; Sekijima Y; Tahara N; Tsukada N; Tsujita K; Tsutsui H; Tomita T; Amano M; Endo J; Okada A; Oda S; Takashio S; Baba Y; Misumi Y; Yazaki M; Anzai T; Ando Y; Isobe M; Kimura T; Fukuda K;
Circ J; 2020 Aug; 84(9):1610-1671. PubMed ID: 32830187
[No Abstract] [Full Text] [Related]
20. [A patient with AL amyloidosis and severe factor X deficiency has been in complete haematological remission with normal factor X activity for 7 years following high-dose chemotherapy. A case study and literature review].
Adam Z; Matýková M; Krejcí M; Pour L; Kissová J; Slechtová M; Chlupová G; Stavarová Y; Simonides J; Penka M; Mayer J; Hájek R
Vnitr Lek; 2010 Jan; 56(1):67-78. PubMed ID: 20184115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
